Compare · ACLS vs TMO
ACLS vs TMO
Side-by-side comparison of Axcelis Technologies Inc. (ACLS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ACLS operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $248.91B, about 68.0x ACLS ($3.66B).
- Over the past year, ACLS is up 37.7% and TMO is up 29.7% - ACLS leads by 8.0 points.
- TMO has been more active in the news (7 items in the past 4 weeks vs 1 for ACLS).
- TMO has more recent analyst coverage (25 ratings vs 18 for ACLS).
- Company
- Axcelis Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $115.13-2.87%
- $696.50+3.45%
- Market cap
- $3.66B
- $248.91B
- 1M return
- +10.95%
- +7.40%
- 1Y return
- +37.67%
- +29.72%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- News (4w)
- 1
- 7
- Recent ratings
- 18
- 25
Axcelis Technologies Inc.
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and Asia. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. It sells its equipment and services to semiconductor chip manufacturers through its direct sales force. The company was founded in 1978 and is headquartered in Beverly, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ACLS
- Axcelis Announces Sponsorship and Participation in the 23rd International Conference on Silicon Carbide and Related Materials (ICSCRM 2026)
- EVP Global Customer Operations Tatnall Christopher covered exercise/tax liability with 136 shares, decreasing direct ownership by 0.49% to 27,491 units (SEC Form 4) (tax liability)
- EVP and Chief Strategy Officer Redinbo Greg covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.59% to 34,816 units (SEC Form 4) (for tax liability)
- Axcelis Announces Sponsorship and Participation in the 25th International Conference on Ion Implantation and Annealing Technology 2026
- Axcelis to Build New Manufacturing Facility in Pyeongtaek, Korea
- Axcelis Announces Participation in Upcoming Investor Conferences
- Axcelis Tech downgraded by Craig Hallum with a new price target
- SEC Form 10-Q filed by Axcelis Technologies Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Axcelis Technologies Inc.
- Axcelis Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)